Details of the Drug Reposition

General Information of This Drug (ID: DM8NODR)

• Drug Name: ATI-502 (DM8NODR)
• Synonyms: ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

3 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Atopic dermatitis	DISTCP41	EA80	Phase 2	[1]
Vitiligo	DISR05SL	ED63.0	Phase 2	[2]
Alopecia	DIS37HU4	ED70	Phase 2	[1]

References

• [1] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)